Compare Stocks: FNCH, VERU, VIRI, and GRCE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FNCH Finch Therapeutics Group	$7.30	$7.30	$2.00 ▼ $16.10	$11.72M	1.18	5,025 shs	N/A
GRCE Grace Therapeutics	$2.10 -1.9%	$2.25	$1.79 ▼ $5.18	$44.18M	0.44	118,287 shs	186,271 shs
VERU Veru	$2.64 -0.4%	$2.59	$2.05 ▼ $7.33	$45.01M	-1.17	250,201 shs	143,542 shs
VIRI Virios Therapeutics	$2.29 -3.0%	$1.83	$0.13 ▼ $1.04	$44.10M	1.58	1.05 million shs	70,171 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FNCH Finch Therapeutics Group	0.00%	0.00%	0.00%	0.00%	-42.06%
GRCE Grace Therapeutics	0.00%	-0.94%	-0.94%	-8.70%	-29.29%
VERU Veru	0.00%	+0.38%	+14.29%	-22.35%	-20.24%
VIRI Virios Therapeutics	-2.97%	-13.58%	+25.14%	+52.67%	-52.39%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FNCH Finch Therapeutics Group	$7.30	$7.30	$2.00 ▼ $16.10	$11.72M	1.18	5,025 shs	N/A
GRCE Grace Therapeutics	$2.10 -1.9%	$2.25	$1.79 ▼ $5.18	$44.18M	0.44	118,287 shs	186,271 shs
VERU Veru	$2.64 -0.4%	$2.59	$2.05 ▼ $7.33	$45.01M	-1.17	250,201 shs	143,542 shs
VIRI Virios Therapeutics	$2.29 -3.0%	$1.83	$0.13 ▼ $1.04	$44.10M	1.58	1.05 million shs	70,171 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FNCH Finch Therapeutics Group	0.00%	0.00%	0.00%	0.00%	-42.06%
GRCE Grace Therapeutics	0.00%	-0.94%	-0.94%	-8.70%	-29.29%
VERU Veru	0.00%	+0.38%	+14.29%	-22.35%	-20.24%
VIRI Virios Therapeutics	-2.97%	-13.58%	+25.14%	+52.67%	-52.39%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FNCH Finch Therapeutics Group	0.00	N/A	N/A	N/A
GRCE Grace Therapeutics	2.00	Hold	$6.00	185.71% Upside
VERU Veru	2.33	Hold	$24.50	828.03% Upside
VIRI Virios Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest FNCH, VERU, VIRI, and GRCE Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/2/2026	VERU Veru	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/19/2026	VERU Veru	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/5/2026	VERU Veru	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/3/2026	GRCE Grace Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
7/21/2026	VERU Veru	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	GRCE Grace Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/6/2026	VERU Veru	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	$14.25 per share	N/A
GRCE Grace Therapeutics	N/A	N/A	N/A	N/A	$2.29 per share	N/A
VERU Veru	N/A	N/A	N/A	N/A	$1.66 per share	N/A
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	$0.20 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FNCH Finch Therapeutics Group	-$74.75M	-$8.82	N/A	N/A	N/A	N/A	-69.14%	-26.92%	N/A
GRCE Grace Therapeutics	-$7.79M	-$1.18	N/A	N/A	N/A	N/A	-36.11%	-34.39%	11/12/2026 (Estimated)
VERU Veru	-$22.73M	-$0.69	N/A	N/A	N/A	N/A	-47.58%	-35.83%	N/A
VIRI Virios Therapeutics	-$5.30M	-$0.27	N/A	N/A	N/A	N/A	-130.33%	-115.00%	N/A

Latest FNCH, VERU, VIRI, and GRCE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q1 2027	GRCE Grace Therapeutics	-$0.1293	-$0.91	-$0.7807	-$0.91	$0.40 million	N/A
8/10/2026	Q3 2026	VERU Veru	-$0.32	-$0.30	+$0.02	-$0.30	$1.70 million	N/A
6/18/2026	Q4 2026	GRCE Grace Therapeutics	-$0.24	-$0.07	+$0.17	-$0.06	$0.90 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	N/A
GRCE Grace Therapeutics	N/A	N/A	N/A	N/A	N/A
VERU Veru	N/A	N/A	N/A	N/A	N/A
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FNCH Finch Therapeutics Group	N/A	3.87	3.87
GRCE Grace Therapeutics	N/A	11.47	11.47
VERU Veru	N/A	4.42	4.42
VIRI Virios Therapeutics	N/A	7.27	7.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FNCH Finch Therapeutics Group	21.77%
GRCE Grace Therapeutics	6.08%
VERU Veru	47.16%
VIRI Virios Therapeutics	9.05%

Insider Ownership

Company	Insider Ownership
FNCH Finch Therapeutics Group	44.90%
GRCE Grace Therapeutics	10.84%
VERU Veru	14.20%
VIRI Virios Therapeutics	12.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FNCH Finch Therapeutics Group	190	1.61 million	885,000	No Data
GRCE Grace Therapeutics	N/A	21.04 million	18.76 million	N/A
VERU Veru	230	17.05 million	14.63 million	Optionable
VIRI Virios Therapeutics	5	19.26 million	16.91 million	No Data

FNCH, VERU, VIRI, and GRCE Headlines

Recent News About These Companies

Die Virios-Therapeutics-Aktie bleibt ein spekulativer Nebenwert im Biotech-Segment

September 5 at 11:34 PM | ad-hoc-news.deA

Digital acceptance and commitment therapy for fibromyalgia – Authors' reply

June 13, 2025 | thelancet.comT

Dogwood Therapeutics Inc (DWTX)

March 16, 2025 | investing.com

Dogwood prices 578,950 shares at $8.26 in registered direct offering

March 13, 2025 | markets.businessinsider.com

Dogwood announces conversion of existing $19.5M in debt to equity

March 12, 2025 | markets.businessinsider.com

DWTX Stock trading resumes

February 11, 2025 | markets.businessinsider.com

Dogwood Therapeutics, Inc. (DWTX)

February 2, 2025 | finance.yahoo.com

DWTX Stock trading halted, volatility trading pause

January 28, 2025 | markets.businessinsider.com

DWTX Stock Hits 52-Week High at $15.74 Amidst Strong Yearly Growth

January 23, 2025 | msn.com

Dogwood announces first patient dosed in Phase 2b trial on Halneuron

January 21, 2025 | markets.businessinsider.com

Polluted communities hold their breath as companies struggle with California’s diesel truck ban

December 10, 2024 | apnews.comA

Dogwood Therapeutics faces potential Nasdaq delisting

November 23, 2024 | uk.investing.com

Dogwood says low-dose IMC-2 treatment reduces long-COVID fatigue

November 18, 2024 | markets.businessinsider.com

Dogwood Study Finds IMC-2 Treatment Reduces Long-COVID Related Fatigue, Sleep Disturbance

November 18, 2024 | markets.businessinsider.com

Inovio Pharmaceuticals (NASDAQ:INO) Stock Quotes, Forecast and News Summary

November 16, 2024 | benzinga.com

DWTX: Phase 2 Long COVID Results Expected Soon

November 12, 2024 | msn.com

Buy Rating for Dogwood Therapeutics: Strategic Initiatives and Promising Pipeline Drive Analyst Confidence

November 10, 2024 | markets.businessinsider.com

Dogwood Therapeutics Reports Q3 2024 Financial Results

November 9, 2024 | markets.businessinsider.com

Dogwood Therapeutics Announces Third Quarter 2024 Financial Results

November 8, 2024 | markets.businessinsider.com

Dogwood Therapeutics, Inc.: Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

October 31, 2024 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

FNCH, VERU, VIRI, and GRCE Company Descriptions

Finch Therapeutics Group NASDAQ:FNCH

$7.30 0.00 (0.00%)

As of 09/4/2026

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

Grace Therapeutics NASDAQ:GRCE

$2.10 -0.04 (-1.87%)

As of 09/4/2026 04:00 PM Eastern

Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.

Veru NASDAQ:VERU

$2.64 -0.01 (-0.38%)

As of 09/4/2026 04:00 PM Eastern

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

Virios Therapeutics NASDAQ:VIRI

$2.29 -0.07 (-2.97%)

As of 09/4/2026

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FNCH, VERU, VIRI, and GRCE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FNCH, VERU, VIRI, and GRCE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FNCH, VERU, VIRI, and GRCE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FNCH, VERU, VIRI, and GRCE Company Descriptions

Finch Therapeutics Group NASDAQ:FNCH

Grace Therapeutics NASDAQ:GRCE

Veru NASDAQ:VERU

Virios Therapeutics NASDAQ:VIRI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FNCH, VERU, VIRI, and GRCE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FNCH, VERU, VIRI, and GRCE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FNCH, VERU, VIRI, and GRCE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FNCH, VERU, VIRI, and GRCE Company Descriptions

Finch Therapeutics Group NASDAQ:FNCH

Grace Therapeutics NASDAQ:GRCE

Veru NASDAQ:VERU

Virios Therapeutics NASDAQ:VIRI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools